A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination with Targeted and Endocrine Therapies in Participants with Advanced Breast Cancer and As a Single Agent in Advanced Solid Tumors
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary) ; RLY-5836 (Primary)
- Indications Advanced breast cancer; Breast cancer; HER2 negative breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Relay Therapeutics
- 07 Mar 2025 Planned End Date changed from 25 Jul 2024 to 28 May 2025.
- 07 Mar 2025 Planned primary completion date changed from 22 Jun 2024 to 7 Mar 2025.
- 17 Feb 2024 Planned End Date changed from 13 Jan 2026 to 25 Jul 2024.